Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins
NDA FilingRetatrutidePositive
AI Analysis
Summary
Eli Lilly announced that Retatrutide, its triple agonist obesity candidate, will be filed for regulatory approval in early 2027 following positive Phase 3 trial results. The drug has demonstrated the most potent weight loss outcomes in late-stage clinical trials.
Clinical Trial Data
Phase
Phase_3
Primary Endpoint
Met
Outcome Details
Two additional Phase 3 obesity wins; filing planned for early 2027
Importance:8/10
Sentiment:
0.80
obesityphase_3regulatory_filingweight_losstriple_agonist
Related Companies
Read the original article
Published by Endpoints News on July 23, 2026 11:11 AM